Índice Bovespa

US Dollar vs BRL

As Melhores Corretoras Online

Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.

Cadastre-se

INCY Incyte Corporation

73,19

1,28 (1,78%)

07 Jan 2025 - Fechado

Atrasado em 15 minutos

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

11/29/2024

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

08/29/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ Vijay Krishna Iyengar

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Incyte (NASDAQ:INCY)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025

Click aqui para mais gráficos Incyte.

Incyte (NASDAQ:INCY)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025

Click aqui para mais gráficos Incyte.

Notícias Incyte Corporation

Form 4 - Statement of changes in beneficial ownership of securities
Sexta, 3 de Janeiro de 2025 (4 dias atrás) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Sexta, 3 de Janeiro de 2025 (5 dias atrás) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Sexta, 3 de Janeiro de 2025 (5 dias atrás) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Terça, 17 de Dezembro de 2024 (3 semanas atrás) • Edgar (US Regulatory)

Incyte to Present at Upcoming Investor Conference
Terça, 17 de Dezembro de 2024 (3 semanas atrás) • Business Wire

Form 144 - Report of proposed sale of securities
Segunda, 16 de Dezembro de 2024 (3 semanas atrás) • Edgar (US Regulatory)

Aktuelle Incyte Tafasitamab (Monjuvi® ) Daten demonstrieren auf dem ASH 2024 deutlich verbessertes progressionsfreies Überleben bei Patienten mit rezidiviertem oder refraktärem follikulärem Lymphom
Quinta, 12 de Dezembro de 2024 (4 semanas atrás) • Business Wire

Les données de dernières minutes d'Incyte sur le tafasitamab (Monjuvi®) à l'ASH 2024 démontrent une survie sensiblement améliorée de la survie sans progression chez les patients atteints de lymphome folliculaire récidivant ou réfractaire
Quinta, 12 de Dezembro de 2024 (4 semanas atrás) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Quarta, 11 de Dezembro de 2024 (4 semanas atrás) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Quarta, 11 de Dezembro de 2024 (4 semanas atrás) • Edgar (US Regulatory)

Incyte Late-Breaking Tafasitamab (Monjuvi®) Data at ASH 2024 Demonstrate Significantly Improved Progression-Free Survival in Patients with Relapsed or Refractory Follicular Lymphoma
Terça, 10 de Dezembro de 2024 (4 semanas atrás) • Business Wire

Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz®) in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer
Sábado, 7 de Dezembro de 2024 (1 mês atrás) • Business Wire

Mais Notícias de Incyte Corporation

Índice Bovespa

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições